Premium
Monte Rosa Therapeutics Inc (GLUE)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Mr. Filip JankuChief Medical Officer | -5,41k | 59,96k | Derivative Exercise and Sale | 13,41 - 24,50 | 2,61k | - |
| 2026-06-29 | Mr. Filip JankuChief Medical Officer | -6,00k | 92,34k | Derivative Exercise and Sale | 7,56 - 22,95 | 1,99k | - |
| 2026-06-29 | Dr. Anthony M. ManningIndependent Director | -10,00k | 189,50k | Derivative Exercise and Sale | 4,16 - 23,11 | 0,00 | - |
| 2026-06-23 | Mr. Filip JankuChief Medical Officer | -5,85k | 118,19k | Automatic Disposition | 20,22 | 1,99k | -74,58% |
| 2026-06-23 | Mr. Filip JankuChief Medical Officer | -36,00k | 491,85k | Derivative Exercise and Sale | 7,56 - 21,42 | 1,99k | - |
| 2026-06-23 | Ms. Jennifer ChampouxCOO | -2,18k | 34,84k | Derivative Exercise and Sale | 3,98 - 20,00 | 4,87k | - |
| 2026-06-23 | Dr. Sharon TownsonChief Scientific Officer | -3,00k | 41,58k | Derivative Exercise and Sale | 6,14 - 20,00 | 5,85k | - |
| 2026-06-17 | Dr. Sharon TownsonChief Scientific Officer | -3,00k | 38,58k | Derivative Exercise and Sale | 6,14 - 19,00 | 5,85k | - |
| 2026-06-17 | Ms. Jennifer ChampouxCOO | -2,18k | 32,68k | Derivative Exercise and Sale | 3,98 - 19,00 | 4,87k | - |
| 2026-06-01 | Dr. Markus WarmuthPresident, CEO & Director | -5,47k | 106,25k | Automatic Disposition | 19,41 - 19,73 | 408,54k | -1,32% |
| 2026-05-29 | Dr. Sharon TownsonChief Scientific Officer | -6,00k | 82,38k | Derivative Exercise and Sale | 6,14 - 19,87 | 5,85k | - |
| 2026-05-27 | Ms. Jennifer ChampouxCOO | -2,18k | 34,84k | Derivative Exercise and Sale | 3,98 - 20,00 | 4,87k | - |
| 2026-05-22 | Ms. Jennifer ChampouxCOO | -2,18k | 32,68k | Derivative Exercise and Sale | 3,98 - 19,00 | 4,87k | - |
| 2026-05-21 | Dr. Anthony M. ManningIndependent Director | -10,00k | 138,50k | Derivative Exercise and Sale | 4,16 - 18,01 | 0,00 | - |
| 2026-05-01 | Dr. Markus WarmuthPresident, CEO & Director | -5,47k | 103,45k | Automatic Disposition | 18,92 | 414,00k | -1,30% |
| 2026-04-14 | Dr. Markus WarmuthPresident, CEO & Director | -8,00k | 141,12k | Vente | 17,64 | 419,47k | -1,87% |
| 2026-04-09 | Mr. Philip NicksonChief Business & Legal Officer | -5,85k | 103,41k | Vente | 17,69 | 0,00 | -100,00% |
| 2026-03-04 | Mr. Edmund DunnInitié | -139,00 | 2,50k | Vente | 17,96 | 22,55k | -0,61% |
| 2026-03-02 | Dr. Markus WarmuthPresident, CEO & Director | -5,47k | 97,97k | Automatic Disposition | 17,92 | 427,47k | -1,26% |
| 2026-02-27 | Mr. Edmund DunnInitié | -25,70k | 120,25k | Derivative Exercise and Sale | 13,41 - 18,10 | 22,69k | - |
| 2026-02-23 | Mr. Filip JankuChief Medical Officer | -9,19k | 179,16k | Vente | 19,50 | 7,84k | -53,97% |
| 2025-11-19 | Versant Venture Management, LLCSociété | -597,93k | 13,75M | Vente | 14,25 - 23,33 | 3,25M | -15,54% |
| 2025-12-04 | Versant Venture Management, LLCSociété | -1,06M | 0,00 | Vente | - | 3,25M | -24,60% |
| 2026-01-07 | Dr. Markus WarmuthPresident, CEO & Director | -5,47k | 128,37k | Automatic Disposition | 23,24 - 24,57 | 432,94k | -1,25% |
| 2026-01-05 | Mr. Philip NicksonChief Business & Legal Officer | -3,16k | 47,86k | Vente | 15,17 | 5,85k | -35,06% |
| 2026-01-05 | Mr. Edmund DunnInitié | -1,04k | 15,76k | Vente | 15,17 | 22,69k | -4,38% |
| 2026-01-05 | Ms. Jennifer ChampouxCOO | -2,63k | 39,88k | Vente | 15,17 | 4,87k | -35,05% |
| 2026-01-05 | Mr. Filip JankuChief Medical Officer | -3,16k | 47,86k | Vente | 15,17 | 17,03k | -15,63% |
| 2026-01-05 | Dr. Markus WarmuthPresident, CEO & Director | -10,14k | 153,75k | Vente | 15,17 | 438,40k | -2,26% |
| 2026-01-05 | Dr. Sharon TownsonChief Scientific Officer | -3,16k | 47,86k | Vente | 15,17 | 5,85k | -35,06% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
